The purpose of this study is to pilot test SLE@Duke, a set of tools to implement the Type 1 \& 2 SLE Model in a clinical setting, as well as to gain an in-depth understanding of providers experiences using the intervention during clinic visits with patients with systemic lupus erythematosus. This record represents Aim 3 of this study.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
16
SLE@Duke is a set of tools to implement the Type 1 \& 2 SLE Model in a clinical setting. The model includes an Electronic Medical Record (EMR) note template, patient-reported outcome measure, and training on how to discuss Type 1 \& 2 SLE.
Duke University Medical Center
Durham, North Carolina, United States
Number of Patients' Rheumatologists Using SLE@Duke
Collected from EMR (electronic medical record). This is a composite measure that includes documentation in the clinic note of any component of SLE@Duke: (1) Type 1 \& 2 SLE Model mentioned, (2) dotphrase used, (3) Type 1 \& Type 2 PGAs (Physician Global Assessments) scored in note, (4) handout mentioned, (5) Type 2 symptoms discussed, or (6) purple sheet documented.
Time frame: Baseline (month 1), intervention period (month 2)
Length of Clinic Visits
Collected from EMR (electronic medical record).
Time frame: Baseline (month 1), intervention period (month 2)
Change in Physician Satisfaction With Visits With Lupus Patients, as Measured by Provider Survey
Satisfaction was measured on a scale of 1-5, where 1 = never and 5 = always in response to the statement: "After seeing a patient with lupus, I leave the exam room feeling satisfied with the encounter."
Time frame: Baseline (month 1), intervention period (month 2)
Number of Lupus Patients With Assessment of Type 1 and 2 SLE in Note
Collected from EMR (electronic medical record).
Time frame: Baseline (month 1), intervention period (month 2)
Number of Lupus Patients With Type 2 SLE Treatment in Note
Collected from EMR (electronic medical record).
Time frame: Baseline (month 1), intervention period (month 2)
Perceived Benefits of SLE@Duke, as Measured by Provider Interviews
In-depth interviews with participating rheumatologists related to the intervention, including acceptability, utility, implementation, integration and practicality of SLE@Duke.
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Perceived Barriers of SLE@Duke, as Measured by Provider Interviews
In-depth interviews with participating rheumatologists related to the intervention, including acceptability, utility, implementation, integration and practicality of SLE@Duke.
Time frame: 4 weeks
How SLE@Duke Fit Into Work Flow, as Measured by Provider Interviews
In-depth interviews with participating rheumatologists related to the intervention, including acceptability, utility, implementation, integration and practicality of SLE@Duke.
Time frame: 4 weeks
Number of Lupus Patients With PRO (Patient-reported Outcomes) in Note
Collected from EMR (electronic medical record).
Time frame: Intervention period (month 2), month 5
Difference in Perceived Quality of Visit, as Measured by Patient Survey
Each question pertaining to quality of visit was measured on a scale of 1-5, where 1 = strongly disagree and 5 = strongly agree. Different patients completed the survey at month 1 and month 2. The scores at month 1 were averaged, then subtracted from the average score at month 2.
Time frame: Baseline (month 1), intervention period (month 2)
Discussion of the Type 1 and 2 Model, as Measured by Patient Survey
The patient survey asked patients to respond "Yes" or "No" in response to the statement: "My rheumatologist discussed Type 1 \& Type 2 lupus with me today."
Time frame: Intervention period (month 2)
Difference in Understanding of Lupus Activity & Treatment Plan, as Measured by Patient Survey
Questions pertaining to understanding were measured on a scale of 1-5, where 1 = strongly disagree and 5 = strongly agree. Different patients completed the survey at month 1 and month 2. The scores at month 1 were averaged, then subtracted from the average score at month 2.
Time frame: Baseline (month 1), intervention period (month 2)
Change in Discussion of the Type 1 and 2 Model, as Measured by Provider Survey
Discussion of the Type 1 \& 2 SLE Model was measured on a scale of 1-5, where 1 = "never" and 5 = "always" in response to the statement: "I discuss the Type 1 \& 2 SLE Model with the patient."
Time frame: Baseline (month 1), intervention period (month 2)
Change in Acceptability of SLE@Duke, as Measured by Provider Survey
Questions pertaining to acceptability of SLE@Duke were measured on a scale of 1-5, where 1 = completely disagree and 5 = completely agree.
Time frame: Baseline (month 1), intervention period (month 2)
Change in Appropriateness of SLE@Duke, as Measured by Provider Survey
Questions pertaining to the appropriateness of SLE@Duke were measured on a scale of 1-5, where 1 = completely disagree and 5 = completely agree.
Time frame: Baseline (month 1), intervention period (month 2)
Change in Feasibility of SLE@Duke, as Measured by Provider Survey
Questions concerning feasibility of SLE@Duke were measured on a scale of 1-5, where 1 = completely disagree and 5 = completely agree.
Time frame: Baseline (month 1), intervention period (month 2)